Refine by
Car T Cell Suppliers & Manufacturers
49 companies found
based inMenlo Park, CALIFORNIA (USA)
Adicet is a biotechnology company engaged in the development of first-in-class off-the-shelf allogeneic gamma delta T cell therapies for cancer and other diseases. Adicet has developed a proprietary cell platform process to activate, engineer and ...
Gamma delta T cells represent a new generation of universal cell therapy. The current engineered autologous alpha beta T cell products have shown significant efficacy in hematological malignancies; however comparable efficacy in solid tumors is yet ...
based inDallas, TEXAS (USA)
Lupagen is a privately held early stage biotech company developing first-in-class bedside enabled cell & gene therapies (CAR-T cell, gene editing and immunotherapy products) based on their patent-pending bedside point-of-care C and GT production and ...
based inHamburg, GERMANY
Revvity Gene Delivery (formerly SIRION Biotech) supports your cell and gene therapy development process ̶ offering solutions for early R&D all the way to clinical applications, with easy transfer of processes and assays into GMP production. ...
Supporting lentiviral vector development for cell therapies; Lentivirus is an efficient tool for fast, efficient, and cost-effective generation of stable homogeneous cell models for strong gene expression or gene ...
based inAllendale, NEW JERSEY (USA)
We are a leading global contract development and manufacturing organization (CDMO) dedicated to the advancement and manufacturing of gene and cell therapy products. Minaris Regenerative Medicine is a leading global contract development and ...
At Minaris Regenerative Medicine, we are committed to bringing together and further developing highly talented, skilled, and dedicated experts with varied backgrounds applicable to gene and cell therapy manufacturing and development. Having this ...
based inSan Diego, CALIFORNIA (USA)
Fate Therapeutics (Nasdaq: FATE) is a clinical-stage biopharmaceutical company dedicated to the development of first-in-class cellular immunotherapies for patients with cancer. We believe that better cell therapies start with better cells. To ...
T cells engineered with chimeric antigen receptors (CARs) have shown exceptional promise as a potentially curative therapy for patients with certain hematologic malignancies. While most researchers ...
based inHolliston, MASSACHUSETTS (USA)
BTX has been at the forefront of electroporation technology since we introduced the first commercially available electroporator in 1983. For over 30 years, we have made it our priority to focus only on electroporation and electrofusion. This focus ...
Easily perform advanced transfection protocols with multiple groups of pulses—each with separate parameters. The AgilePulse™ PLUS Bipolar Transfection System is designed for efficient transfection of mammalian cells and tissues. This ...
based inOxford, UNITED KINGDOM
ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...
ProM1™ MHC Class I Monomers, biotin labeled enabling specialist assays for defined MHC Class I peptide target ...
based inGuro-gu, SOUTH KOREA
NanoEntek possesses a key piece of Bio-MEMS technology that seamlessly integrates biotechnology with Micro-electro Mechanical Systems(MEMS), which is heralded as the most advanced technology in the 21st century. To realize this technology, ...
based inSan Carlos, CALIFORNIA (USA)
CellFE is a venture-backed company with a mission to make advanced therapies accessible to all by transforming the way gene therapies are manufactured. The company uses a microfluidics-based cell engineering platform that can be adapted universally ...
based inMonmouth Junction, NEW JERSEY (USA)
MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet ...
ML-T7 blocks Tim-3 interactions with PtdSer and CEACAM1.ML-T7 not only enhances the antitumor activity of adoptive transfer therapy with cytotoxic T lymphocytes (CTLs) and CAR T ...
based inNew York, NEW YORK (USA)
Immunai was founded in December 2018. We are a multidisciplinary team of immunologists, genomics technologists, computer scientists, engineers, mathematicians and operators singularly focused on solving an audacious challenge. Backed by some of the ...
Immunai’s end-to-end single-cell platform enables high resolution profiling of the immune system at industrial scale, generating biological insights that accelerate R&D and power novel ...
based inAtlanta, GEORGIA (US) (USA)
Transforming the manufacture of cell-based therapeutics into a large-scale, lower-cost, reproducible, and high-quality engineered process, for broad industry and clinical ...
CMaT graduate students enroll in a new CMaT-designed courses and complete mentored research experiences focused on cell manufacturing barriers as part of a program designed to train them in the key skill sets prioritized by our industry and clinical ...
based inSão Paulo, BRAZIL
Celluris is the first company in Latin America to develop personalized treatment for cancer patients through CAR-T immunotherapy. This technique is based on the modification of the patient’s own cells into recognizing the tumor as a target, fighting ...
based inLebanon, NEW HAMPSHIRE (USA)
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging diseases. We are a recognized leader with a rich stable of discoveries, developed in concert with premiere ...
Celdara Medical gives hope and health to patients by transforming academic innovations into medicines that cure the world’s most challenging ...
based inNotting Hill, AUSTRALIA
Cartherics is developing its novel “off-the-shelf” (allogeneic) immune therapy products for the treatment of cancer based on immune killer cells. The company is developing large-scale manufacture of these CAR-iNK cells for application in human ...
This technology arms the patient’s own T cells with CARs, which enable them to “seek and destroy” cancer ...
based in, NEW JERSEY (USA)
Tevogen Bio is driven by a team of distinguished scientists and experienced biopharmaceutical leaders who have developed and commercialized multiple franchises. In collaboration with key strategic partners, the company moved its lead product from ...
Innovative Science in Virology, Oncology, and Neurology; Allogeneic CD8+ T cell therapies from a single donor to treat thousands for the first ...
based inHolytown, UNITED KINGDOM
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. Our mission is to ...
At TC BioPharm, we apply chimeric antigen receptor T cell (CAR-T) technology to gamma delta T (GDT) cells. This takes advantage of the endogenous ...
based inCambridge, MASSACHUSETTS (USA)
Many of us pursuing work in the biotechnology industry are inspired by a loved one who is living with a disease or the loss of someone in our community. Rare genetic and oncological and immunological diseases not only affect the people living with ...
We plan to initiate patient screening for a first-in-human Phase 1 study of NTLA-5001, a WT1-directed TCR T cell therapy for the treatment of AML, by the end of 2021. Our first ex vivo development candidate seeks to treat acute myeloid leukemia ...
based inMilano, ITALY
We are a clinical-stage biotechnology company pioneering the treatment of cancers with a technology platform that allows the direct delivery of immunotherapeutic payloads within the tumor microenvironment. Intrinsic resistance significantly reduces ...
based inAbingdon, UNITED KINGDOM
PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of ...
Our clinically validated T-SIGn® viral vector platform delivers multiple transgene payloads that re-program the tumor microenvironment of both primary and metastatic tumors. Our platform can integrate rationally designed synthetic agents to ...